Sunesis Pharmaceuticals, Inc.
(NASDAQ : SNSS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
0.17%358.711.2%$830.53m
AMGNAmgen Inc.
-0.66%190.491.2%$543.11m
CELGCelgene Corporation
-0.28%85.101.2%$507.54m
GILDGilead Sciences, Inc.
0.42%77.370.9%$473.45m
VRTXVertex Pharmaceuticals Incorporated
-1.51%177.401.9%$313.54m
REGNRegeneron Pharmaceuticals, Inc.
-0.17%367.112.6%$276.88m
ILMNIllumina, Inc.
0.66%311.153.5%$269.38m
BLUEBluebird Bio, Inc.
0.78%180.3515.7%$197.52m
SRPTSarepta Therapeutics, Inc.
-1.64%133.3116.6%$196.81m
ALXNAlexion Pharmaceuticals, Inc.
0.05%135.162.0%$178.57m
NKTRNektar Therapeutics
-0.71%48.735.6%$172.03m
EXASExact Sciences Corporation
0.02%67.6225.4%$155.70m
EXELExelixis, Inc.
-0.23%21.296.4%$135.36m
BMRNBioMarin Pharmaceutical Inc.
-0.94%101.904.4%$122.64m
AAgilent Technologies, Inc.
-0.45%63.861.5%$110.57m

Company Profile

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.